:

Homeland Security

DoD Awards Morphotek $1.7M for Bio-defense Therapeutics

DDN

Wednesday, June 25th, 2008

SHARE:

Morphotek has received $1.7 million in funding approval from the Defense Department to further develop biologic-based monoclonal antibody (mAb) therapies targeting staphylococcal toxins as well as staph itself for the treatment of infectious diseases. Morphotek says it has developed multiple mAbs that are able to bind and neutralize the toxic effects elicited by microbial pathogens and is applying its technology to generate potent therapeutic mAbs to treat diseases caused by potential bio-warfare pathogens. Morphotek is a subsidiary of Eisai Corp.…

Congress

Warren And Sheehy Renew Call for “Right to Repair” In NDAA

Sen. Elizabeth Warren (D-Mass.) and Sen. Timothy Sheehy (R-Mont.), two members of the Senate Armed Services Committee (SASC), are renewing their call for “Right to Repair” language in the National […]

HASC Looks To Restrict USV Deliveries Without Navy CONOPS And Strategy

The House Armed Services Committee’s (HASC) fiscal year 2027 defense policy draft bill aims to restrict the Navy’s use of unmanned surface vessels (USV) until it decides on key factors […]

Congress

Gaps In Army’s Tactical Counter-Drone Capabilities Remain Concern Of HASC

A draft defense policy bill released this week says the Army is fielding counter-drone capabilities for defense of fixed sites and maneuver forces but suggests that troops at the lowest […]

Army

HASC Wants Closer Look At Army’s SBMC Program, Cites Avoiding Past IVAS Missteps

The House Armed Services Committee (HASC) wants a closer look at the Army’s Soldier Borne Mission Command (SBMC) effort, citing support for the development program while expressing caution to avoid […]